Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Heska Co. stock logo
HSKA
Heska
$119.99
$119.09
$57.83
$120.03
$1.31B1.58241,932 shsN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$79.21
-0.5%
$82.57
$73.11
$126.89
$5.56B0.121.02 million shs329,518 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.60
-0.5%
$5.09
$3.81
$29.30
$516.19M1.911.26 million shs463,756 shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$10.72
-0.1%
$8.77
$5.90
$28.18
$1.11B2.212.97 million shs2.81 million shs
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$30.17
0.0%
$30.21
$23.77
$49.45
$2.04B0.071.14 million shs999,310 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Heska Co. stock logo
HSKA
Heska
0.00%0.00%0.00%0.00%0.00%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.00%-2.80%-0.53%-12.88%-0.44%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.00%+6.67%+5.86%-31.12%-77.56%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
0.00%+12.08%+39.70%+61.61%-53.31%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.00%+4.49%-2.94%+7.23%-2.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4533 of 5 stars
3.51.00.04.22.22.51.9
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
4.1686 of 5 stars
4.13.00.04.10.01.70.6
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
4.7232 of 5 stars
4.33.00.04.72.12.50.6
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
4.469 of 5 stars
3.22.00.03.82.21.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Heska Co. stock logo
HSKA
Heska
0.00
N/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$130.5064.75% Upside
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.13
Hold$14.38156.87% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.65
Moderate Buy$33.37211.42% Upside
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
2.43
Hold$44.3346.97% Upside

Current Analyst Ratings Breakdown

Latest MYGN, QDEL, HSKA, LNTH, and NTLA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$7.00
6/16/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/3/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $54.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00 ➝ $7.00
5/29/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/21/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.00
5/20/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/19/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.00
5/15/2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.00
5/12/2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $45.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Heska Co. stock logo
HSKA
Heska
$257.31M5.09$1.69 per share70.99$39.00 per share3.08
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.57$6.99 per share11.34$15.65 per share5.06
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$837.60M0.62$1.00 per share5.60$7.70 per share0.73
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$57.88M19.18N/AN/A$8.56 per share1.25
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$2.78B0.73$35.49 per share0.85$44.38 per share0.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Heska Co. stock logo
HSKA
Heska
-$19.89M-$1.93N/A83.33N/A-7.86%0.94%0.67%N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5222.5012.55N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
-$2.05B-$4.97N/A9.40N/A-12.07%4.71%2.21%7/30/2025 (Estimated)

Latest MYGN, QDEL, HSKA, LNTH, and NTLA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
7/30/2025Q2 2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$0.0122N/AN/AN/A$612.36 millionN/A
5/8/2025Q1 2025
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/7/2025Q1 2025
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million
5/6/2025Q1 2025
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Heska Co. stock logo
HSKA
Heska
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Heska Co. stock logo
HSKA
Heska
0.23
5.64
4.12
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.08
1.90
1.71
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
4.90
4.90
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.70
1.20
0.66

Institutional Ownership

CompanyInstitutional Ownership
Heska Co. stock logo
HSKA
Heska
99.01%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
99.00%

Insider Ownership

CompanyInsider Ownership
Heska Co. stock logo
HSKA
Heska
12.30%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.40%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.10%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
0.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Heska Co. stock logo
HSKA
Heska
80810.91 million9.57 millionNot Optionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million68.15 millionOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70092.18 million89.97 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600103.58 million100.37 millionOptionable
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
6,60067.63 million67.09 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Heska stock logo

Heska NASDAQ:HSKA

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$79.21 -0.41 (-0.51%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$79.21 0.00 (0.00%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$5.60 -0.03 (-0.53%)
Closing price 07/3/2025 02:38 PM Eastern
Extended Trading
$5.60 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$10.72 -0.02 (-0.14%)
Closing price 07/3/2025 03:59 PM Eastern
Extended Trading
$10.66 -0.06 (-0.56%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

QuidelOrtho stock logo

QuidelOrtho NASDAQ:QDEL

$30.16 -0.02 (-0.05%)
Closing price 07/3/2025 01:23 PM Eastern
Extended Trading
$30.16 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.